These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 25691052)
1. Activation of RAS family members confers resistance to ROS1 targeting drugs. Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052 [TBL] [Abstract][Full Text] [Related]
2. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157 [TBL] [Abstract][Full Text] [Related]
3. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332 [TBL] [Abstract][Full Text] [Related]
4. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
5. [A new target in non-small cell lung cancer: ROS1 fusion gene]. Cai WJ; Su B Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291 [No Abstract] [Full Text] [Related]
7. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056 [TBL] [Abstract][Full Text] [Related]
8. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229 [TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245 [TBL] [Abstract][Full Text] [Related]
10. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554 [TBL] [Abstract][Full Text] [Related]